Guggenheim Capital LLC Insmed Inc Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Insmed Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 37,305 shares of INSM stock, worth $2.63 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

37,305

Previous 36,500 2.21%

Holding current value

$2.63 Million

Previous $2.45 Million 11.37%

% of portfolio

0.02%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$62.0 - $79.01 $49,910 - $63,603	805 Added 2.21%	37,305 $2.72 Million
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $312,224 - $989,324	-14,192 Reduced 28.0%	36,500 $2.45 Million
Q1 2024 May 14, 2024	BUY	$25.72 - $29.94 $171,861 - $200,059	6,682 Added 15.18%	50,692 $1.38 Million
Q4 2023 Feb 14, 2024	SELL	$23.42 - $31.74 $185,205 - $250,999	-7,908 Reduced 15.23%	44,010 $1.36 Million
Q3 2023 Nov 14, 2023	SELL	$19.86 - $26.93 $172,007 - $233,240	-8,661 Reduced 14.3%	51,918 $1.31 Million
Q2 2023 Aug 11, 2023	SELL	$16.44 - $21.1 $37,121 - $47,643	-2,258 Reduced 3.59%	60,579 $1.28 Million
Q1 2023 May 10, 2023	BUY	$16.26 - $21.73 $1.02 Million - $1.37 Million	62,837 New	62,837 $1.07 Million
Q2 2018 Aug 14, 2018	SELL	$20.0 - $29.72 $2.08 Million - $3.09 Million	-103,962 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$21.69 - $32.99 $177,489 - $269,957	8,183 Added 8.54%	103,962 $2.34 Million
Q4 2017 Feb 14, 2018	BUY	$26.43 - $31.78 $2.53 Million - $3.04 Million	95,779	95,779 $2.99 Million

Others Institutions Holding INSM

# of Institutions

466

Shares Held

180M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.56B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Insmed Inc Transaction History